



State of Wisconsin
2025 - 2026 LEGISLATURE

LRBb0731/1

JPC:cdc

**ASSEMBLY AMENDMENT 11,
TO ASSEMBLY SUBSTITUTE AMENDMENT 2,
TO ASSEMBLY BILL 50**

July 2, 2025 - Offered by Representatives SUBECK, ANDERSON, ANDRACA, ARNEY, BARE, BILLINGS, BROWN, CLANCY, CRUZ, DESANTO, DESMIDT, DOYLE, EMERSON, FITZGERALD, GOODWIN, HAYWOOD, HONG, HYSELL, J. JACOBSON, JOERS, JOHNSON, KIRSCH, MADISON, MAYADEV, MCCARVILLE, MCGUIRE, MIRESE, MOORE OMOKUNDE, NEUBAUER, PALMERI, PHELPS, PRADO, RIVERA-WAGNER, ROE, SHEEHAN, SINICKI, SNODGRASS, SPAUDE, STROUD, STUBBS, TAYLOR, TENORIO, UDELL and VINING.

1 At the locations indicated, amend the substitute amendment as follows:

2 **1.** At the appropriate places, insert all of the following:

3 **“SECTION 1.** 15.07 (3) (bm) 7. of the statutes is created to read:

4 15.07 (3) (bm) 7. The prescription drug affordability review board shall meet
5 at least 4 times each year.

6 **SECTION 2.** 15.735 of the statutes is created to read:

7 **15.735 Same; attached board.** (1) There is created a prescription drug
8 affordability review board attached to the office of the commissioner of insurance
9 under s. 15.03. The board shall consist of the following members:

10 (a) The commissioner of insurance or his or her designee.

11 (b) Two members appointed for 4-year terms who represent the

1 pharmaceutical drug industry, including pharmaceutical drug manufacturers and
2 wholesalers. At least one of the members appointed under this paragraph shall be
3 a licensed pharmacist.

4 (c) Two members appointed for 4-year terms who represent the health
5 insurance industry, including insurers and pharmacy benefit managers.

6 (d) Two members appointed for 4-year terms who represent the health care
7 industry, including hospitals, physicians, pharmacies, and pharmacists. At least
8 one of the members appointed under this paragraph shall be a licensed
9 practitioner.

10 (e) Two members appointed for 4-year terms who represent the interests of
11 the public.

12 (2) A member appointed under sub. (1), except for a member appointed under
13 sub. (1) (b), may not be an employee of, a board member of, or a consultant to a drug
14 manufacturer or trade association for drug manufacturers.

15 (3) Any conflict of interest, including any financial or personal association,
16 that has the potential to bias or has the appearance of biasing an individual's
17 decision in matters related to the board or the conduct of the board's activities shall
18 be considered and disclosed when appointing that individual to the board under
19 sub. (1).

20 **SECTION 3.** 20.145 (1) (g) 5. of the statutes is created to read:

21 20.145 (1) (g) 5. All moneys received from the regulation of pharmacy benefit
22 managers, pharmacy benefit management brokers, pharmacy benefit management

1 consultants, pharmacy services administration organizations, and pharmaceutical
2 representatives.

3 **SECTION 4.** 601.575 of the statutes is created to read:

4 **601.575 Prescription drug importation program. (1) IMPORTATION**
5 **PROGRAM REQUIREMENTS.** The commissioner, in consultation with persons
6 interested in the sale and pricing of prescription drugs and appropriate officials
7 and agencies of the federal government, shall design and implement a prescription
8 drug importation program for the benefit of residents of this state, that generates
9 savings for residents, and that satisfies all of the following:

10 (a) The commissioner shall designate a state agency to become a licensed
11 wholesale distributor or to contract with a licensed wholesale distributor and shall
12 seek federal certification and approval to import prescription drugs.

13 (b) The program shall comply with relevant requirements of 21 USC 384,
14 including safety and cost savings requirements.

15 (c) The program shall import prescription drugs from Canadian suppliers
16 regulated under any appropriate Canadian or provincial laws.

17 (d) The program shall have a process to sample the purity, chemical
18 composition, and potency of imported prescription drugs.

19 (e) The program shall import only those prescription drugs for which
20 importation creates substantial savings for residents of this state and only those
21 prescription drugs that are not brand-name drugs and that have fewer than 4
22 competitor prescription drugs in the United States.

1 (f) The commissioner shall ensure that prescription drugs imported under the
2 program are not distributed, dispensed, or sold outside of this state.

3 (g) The program shall ensure all of the following:

4 1. Participation by any pharmacy or health care provider in the program is
5 voluntary.

6 2. Any pharmacy or health care provider participating in the program has the
7 appropriate license or other credential in this state.

8 3. Any pharmacy or health care provider participating in the program charges
9 a consumer or health plan the actual acquisition cost of the imported prescription
10 drug that is dispensed.

11 (h) The program shall ensure that a payment by a health plan or health
12 insurance policy for a prescription drug imported under the program reimburses no
13 more than the actual acquisition cost of the imported prescription drug that is
14 dispensed.

15 (i) The program shall ensure that any health plan or health insurance policy
16 participating in the program does all of the following:

17 1. Maintains a formulary and claims payment system with current
18 information on prescription drugs imported under the program.

19 2. Bases cost-sharing amounts for participants or insureds under the plan or
20 policy on no more than the actual acquisition cost of the prescription drug imported
21 under the program that is dispensed to the participant or insured.

22 3. Demonstrates to the commissioner or a state agency designated by the

1 commissioner how premiums under the plan or policy are affected by savings on
2 prescription drugs imported under the program.

3 (j) Any wholesale distributor importing prescription drugs under the program
4 shall limit its profit margin to the amount established by the commissioner or a
5 state agency designated by the commissioner.

6 (k) The program may not import any generic prescription drug that would
7 violate federal patent laws on branded products in the United States.

8 (L) The program shall comply with tracking and tracing requirements of 21
9 USC 360eee and 360eee-1, to the extent practical and feasible, before the
10 prescription drug to be imported comes into the possession of this state's wholesale
11 distributor and fully after the prescription drug to be imported is in the possession
12 of this state's wholesale distributor.

13 (m) The program shall establish a fee or other mechanism to finance the
14 program that does not jeopardize significant savings to residents of this state.

15 (n) The program shall have an audit function that ensures all of the following:

16 1. The commissioner has a sound methodology to determine the most cost-
17 effective prescription drugs to include in the program.

18 2. The commissioner has a process in place to select Canadian suppliers that
19 are high quality, high performing, and in full compliance with Canadian laws.

20 3. Prescription drugs imported under the program are pure, unadulterated,
21 potent, and safe.

22 4. The program is complying with the requirements of this subsection.

1 5. The program is adequately financed to support administrative functions of
2 the program while generating significant cost savings to residents of this state.

3 6. The program does not put residents of this state at a higher risk than if the
4 program did not exist.

5 7. The program provides and is projected to continue to provide substantial
6 cost savings to residents of this state.

7 **(2) ANTICOMPETITIVE BEHAVIOR.** The commissioner, in consultation with the
8 attorney general, shall identify the potential for and monitor anticompetitive
9 behavior in industries affected by a prescription drug importation program.

10 **(3) APPROVAL OF PROGRAM DESIGN; CERTIFICATION.** No later than the first day
11 of the 7th month beginning after the effective date of this subsection [LRB
12 inserts date], the commissioner shall submit to the joint committee on finance a
13 report that includes the design of the prescription drug importation program in
14 accordance with this section. The commissioner may not submit the proposed
15 program to the federal department of health and human services unless the joint
16 committee on finance approves the proposed program. Within 14 days of the date of
17 approval by the joint committee on finance of the proposed program, the
18 commissioner shall submit to the federal department of health and human services
19 a request for certification of the approved program.

20 **(4) IMPLEMENTATION OF CERTIFIED PROGRAM.** After the federal department of
21 health and human services certifies the prescription drug importation program
22 submitted under sub. (3), the commissioner shall begin implementation of the
23 program, and the program shall be fully operational by 180 days after the date of

1 certification by the federal department of health and human services. The
2 commissioner shall do all of the following to implement the program to the extent
3 the action is in accordance with other state laws and the certification by the federal
4 department of health and human services:

5 (a) Become a licensed wholesale distributor, designate another state agency to
6 become a licensed wholesale distributor, or contract with a licensed wholesale
7 distributor.

8 (b) Contract with one or more Canadian suppliers that meet the criteria in
9 sub. (1) (c) and (n).

10 (c) Create an outreach and marketing plan to communicate with and provide
11 information to health plans and health insurance policies, employers, pharmacies,
12 health care providers, and residents of this state on participating in the program.

13 (d) Develop and implement a registration process for health plans and health
14 insurance policies, pharmacies, and health care providers interested in
15 participating in the program.

16 (e) Create a publicly accessible source for listing prices of prescription drugs
17 imported under the program.

18 (f) Create, publicize, and implement a method of communication to promptly
19 answer questions from and address the needs of persons affected by the
20 implementation of the program before the program is fully operational.

21 (g) Establish the audit functions under sub. (1) (n) with a timeline to complete
22 each audit function every 2 years.

1 (h) Conduct any other activities determined by the commissioner to be
2 important to successful implementation of the program.

3 (5) REPORT. By January 1 and July 1 of each year, the commissioner shall
4 submit to the joint committee on finance a report including all of the following:

5 (a) A list of prescription drugs included in the prescription drug importation
6 program under this section.

7 (b) The number of pharmacies, health care providers, and health plans and
8 health insurance policies participating in the prescription drug importation
9 program under this section.

10 (c) The estimated amount of savings to residents of this state, health plans
11 and health insurance policies, and employers resulting from the implementation of
12 the prescription drug importation program under this section reported from the
13 date of the previous report under this subsection and from the date the program
14 was fully operational.

15 (d) Findings of any audit functions under sub. (1) (n) completed since the date
16 of the previous report under this subsection.

17 (6) RULEMAKING. The commissioner may promulgate any rules necessary to
18 implement this section.

19 **SECTION 5.** Subchapter VI (title) of chapter 601 [precedes 601.78] of the
20 statutes is created to read:

21 **CHAPTER 601**

22 **SUBCHAPTER VI**

23 **PRESCRIPTION DRUG**

1 AFFORDABILITY REVIEW BOARD

2 **SECTION 6.** 601.78 of the statutes is created to read:3 **601.78 Definitions.** In this subchapter:4 (1) “Biologic” means a drug that is produced or distributed in accordance with
5 a biologics license application approved under 21 CFR 601.20.6 (2) “Biosimilar” means a drug that is produced or distributed in accordance
7 with a biologics license application approved under 42 USC 262 (k) (3).8 (3) “Board” means the prescription drug affordability review board
9 established under s. 15.735 (1).10 (4) “Brand name drug” means a drug that is produced or distributed in
11 accordance with an original new drug application approved under 21 USC 355 (c),
12 other than an authorized generic drug, as defined in 42 CFR 447.502.13 (5) “Financial benefit” includes an honorarium, fee, stock, the value of the
14 stock holdings of a member of the board or any immediate family member of the
15 member of the board, and any direct financial benefit deriving from the finding of a
16 review conducted under s. 601.79.

17 (6) “Generic drug” means any of the following:

18 (a) A retail drug that is marketed or distributed in accordance with an
19 abbreviated new drug application approved under 21 USC 355 (j).

20 (b) An authorized generic drug, as defined in 42 CFR 447.502.

21 (c) A drug that entered the market prior to 1962 and was not originally
22 marketed under a new drug application.

23 (7) “Immediate family member” means a spouse, grandparent, parent,

1 sibling, child, stepchild, or grandchild or the spouse of a grandparent, parent,
2 sibling, child, stepchild, or grandchild.

3 (8) “Manufacturer” means an entity that does all of the following:

4 (a) Engages in the manufacture of a prescription drug product or enters into
5 a lease with another entity to market and distribute a prescription drug product
6 under the entity’s own name.

7 (b) Sets or changes the wholesale acquisition cost of the prescription drug
8 product described in par. (a).

9 (9) “Pharmacy benefit manager” has the meaning given in s. 632.865 (1) (c).

10 (10) “Prescription drug product” means a brand name drug, a generic drug, a
11 biologic, or a biosimilar.

12 **SECTION 7.** 601.785 of the statutes is created to read:

13 **601.785 Prescription drug affordability review board.** (1) MISSION.

14 The purpose of the board is to protect state residents, the state, local governments,
15 health plans, health care providers, pharmacies licensed in this state, and other
16 stakeholders of the health care system in this state from the high costs of
17 prescription drug products.

18 (2) POWERS AND DUTIES. (a) The board shall do all of the following:

19 1. Meet in open session at least 4 times per year to review prescription drug
20 product pricing information in the manner described in subd. 2., except that the
21 chairperson may cancel or postpone a meeting if there is no business to transact.

22 2. To the extent practicable, access and assess pricing information for
23 prescription drug products by doing all of the following:

1 a. Accessing and assessing information from other states by entering into
2 memoranda of understanding with other states to which manufacturers report
3 pricing information.

4 b. Assessing spending for specific prescription drug products in this state.

5 c. Accessing other available pricing information.

6 (b) The board may do any of the following:

7 1. Promulgate rules for the administration of this subchapter.

8 2. Enter into a contract with an independent 3rd party for any service
9 necessary to carry out the powers and duties of the board. Unless written
10 permission is granted by the board, any person with whom the board contracts may
11 not release, publish, or otherwise use any information to which the person has
12 access under the contract.

13 (c) The board shall establish and maintain a website to provide public notices
14 and make meeting materials available under sub. (3) (a) and to disclose conflicts of
15 interest under sub. (4) (d).

16 **(3) MEETING REQUIREMENTS.** (a) Pursuant to s. 19.84, the board shall provide
17 public notice of each board meeting at least 2 weeks prior to the meeting and shall
18 make the materials for each meeting publicly available at least one week prior to
19 the meeting.

20 (b) Notwithstanding s. 19.84 (2), the board shall provide an opportunity for
21 public comment at each open meeting and shall provide the public with the
22 opportunity to provide written comments on pending decisions of the board.

23 (c) Notwithstanding subch. V of ch. 19, any portion of a meeting of the board

1 concerning proprietary data and information shall be conducted in closed session
2 and shall in all respects remain confidential.

3 (d) The board may allow expert testimony at any meeting, including when the
4 board meets in closed session.

5 (4) CONFLICTS OF INTEREST. (a) A member of the board shall recuse himself
6 or herself from a decision by the board relating to a prescription drug product if the
7 member or an immediate family member of the member has received or could
8 receive any of the following:

9 1. A direct financial benefit deriving from a determination, or a finding of a
10 study or review, by the board relating to the prescription drug product.

11 2. A financial benefit in excess of \$5,000 in a calendar year from any person
12 who owns, manufactures, or provides a prescription drug product to be studied or
13 reviewed by the board.

14 (b) A conflict of interest under this subsection shall be disclosed by the board
15 when hiring board staff, by the appointing authority when appointing members to
16 the board, and by the board when a member of the board is recused from any
17 decision relating to a review of a prescription drug product.

18 (c) A conflict of interest under this subsection shall be disclosed no later than
19 5 days after the conflict is identified, except that, if the conflict is identified within
20 5 days of an open meeting of the board, the conflict shall be disclosed prior to the
21 meeting.

22 (d) The board shall disclose a conflict of interest under this subsection on the
23 board's website unless the chairperson of the board recuses the member from a

1 final decision relating to a review of the prescription drug product. The disclosure
2 shall include the type, nature, and magnitude of the interests of the member
3 involved.

4 (e) A member of the board or a 3rd-party contractor may not accept any gift or
5 donation of services or property that indicates a potential conflict of interest or has
6 the appearance of biasing the work of the board.

7 **SECTION 8.** 601.79 of the statutes is created to read:

8 **601.79 Drug cost affordability review. (1) IDENTIFICATION OF DRUGS.**

9 The board shall identify prescription drug products that are any of the following:

10 (a) A brand name drug or biologic that, as adjusted annually to reflect
11 adjustments to the U.S. consumer price index for all urban consumers, U.S. city
12 average, as determined by the U.S. department of labor, has a launch wholesale
13 acquisition cost of at least \$30,000 per year or course of treatment.

14 (b) A brand name drug or biologic that, as adjusted annually to reflect
15 adjustments to the U.S. consumer price index for all urban consumers, U.S. city
16 average, as determined by the U.S. department of labor, has a wholesale acquisition
17 cost that has increased by at least \$3,000 during a 12-month period.

18 (c) A biosimilar that has a launch wholesale acquisition cost that is not at
19 least 15 percent lower than the referenced brand biologic at the time the biosimilar
20 is launched.

21 (d) A generic drug that has a wholesale acquisition cost, as adjusted annually
22 to reflect adjustments to the U.S. consumer price index for all urban consumers,

1 U.S. city average, as determined by the U.S. department of labor, that meets all of
2 the following conditions:

3 1. Is at least \$100 for a supply lasting a patient for a period of 30 consecutive
4 days based on the recommended dosage approved for labeling by the federal food
5 and drug administration, a supply lasting a patient for a period of fewer than 30
6 days based on the recommended dosage approved for labeling by the federal food
7 and drug administration, or one unit of the drug if the labeling approved by the
8 federal food and drug administration does not recommend a finite dosage.

9 2. Increased by at least 200 percent during the preceding 12-month period, as
10 determined by the difference between the resulting wholesale acquisition cost and
11 the average of the wholesale acquisition cost reported over the preceding 12
12 months.

13 (e) Other prescription drug products, including drugs to address public health
14 emergencies, that may create affordability challenges for the health care system
15 and patients in this state.

16 **(2) AFFORDABILITY REVIEW.** (a) After identifying prescription drug products
17 under sub. (1), the board shall determine whether to conduct an affordability
18 review for each identified prescription drug product by seeking stakeholder input
19 about the prescription drug product and considering the average patient cost share
20 of the prescription drug product.

21 (b) The information used to conduct an affordability review under par. (a) may
22 include any document and research related to the manufacturer's selection of the
23 introductory price or price increase of the prescription drug product, including life

1 cycle management, net average price in this state, market competition and context,
2 projected revenue, and the estimated value or cost-effectiveness of the prescription
3 drug product.

4 (c) The failure of a manufacturer to provide the board with information for an
5 affordability review under par. (b) does not affect the authority of the board to
6 conduct the review.

7 **(3) AFFORDABILITY CHALLENGE.** When conducting an affordability review of a
8 prescription drug product under sub. (2), the board shall determine whether use of
9 the prescription drug product that is fully consistent with the labeling approved by
10 the federal food and drug administration or standard medical practice has led or
11 will lead to an affordability challenge for the health care system in this state,
12 including high out-of-pocket costs for patients. To the extent practicable, in
13 determining whether a prescription drug product has led or will lead to an
14 affordability challenge, the board shall consider all of the following factors:

15 (a) The wholesale acquisition cost for the prescription drug product sold in
16 this state.

17 (b) The average monetary price concession, discount, or rebate the
18 manufacturer provides, or is expected to provide, to health plans in this state as
19 reported by manufacturers and health plans, expressed as a percentage of the
20 wholesale acquisition cost for the prescription drug product under review.

21 (c) The total amount of the price concessions, discounts, and rebates the
22 manufacturer provides to each pharmacy benefit manager for the prescription drug

1 product under review, as reported by the manufacturer and pharmacy benefit
2 manager and expressed as a percentage of the wholesale acquisition cost.

3 (d) The price at which therapeutic alternatives to the prescription drug
4 product have been sold in this state.

5 (e) The average monetary concession, discount, or rebate the manufacturer
6 provides or is expected to provide to health plan payors and pharmacy benefit
7 managers in this state for therapeutic alternatives to the prescription drug product.

8 (f) The costs to health plans based on patient access consistent with labeled
9 indications by the federal food and drug administration and recognized standard
10 medical practice.

11 (g) The impact on patient access resulting from the cost of the prescription
12 drug product relative to insurance benefit design.

13 (h) The current or expected dollar value of drug-specific patient access
14 programs that are supported by the manufacturer.

15 (i) The relative financial impacts to health, medical, or social services costs
16 that can be quantified and compared to baseline effects of existing therapeutic
17 alternatives to the prescription drug product.

18 (j) The average patient copay or other cost sharing for the prescription drug
19 product in this state.

20 (k) Any information a manufacturer chooses to provide.

21 (L) Any other factors as determined by the board by rule.

22 (4) UPPER PAYMENT LIMIT. (a) If the board determines under sub. (3) that use
23 of a prescription drug product has led or will lead to an affordability challenge, the

1 board shall establish an upper payment limit for the prescription drug product after
2 considering all of the following:

- 3 1. The cost of administering the drug.
- 4 2. The cost of delivering the drug to consumers.
- 5 3. Other relevant administrative costs related to the drug.

6 (b) For a prescription drug product identified in sub. (1) (b) or (d) 2., the board
7 shall solicit information from the manufacturer regarding the price increase. To
8 the extent that the price increase is not a result of the need for increased
9 manufacturing capacity or other effort to improve patient access during a public
10 health emergency, the board shall establish an upper payment limit under par. (a)
11 that is equal to the cost to consumers prior to the price increase.

12 (c) 1. The upper payment limit established under this subsection shall apply
13 to all purchases and payor reimbursements of the prescription drug product
14 dispensed or administered to individuals in this state in person, by mail, or by other
15 means.

16 2. Notwithstanding subd. 1., while state-sponsored and state-regulated
17 health plans and health programs shall limit drug reimbursements and drug
18 payment to no more than the upper payment limit established under this
19 subsection, a plan subject to the Employee Retirement Income Security Act of 1974
20 or Part D of Medicare under 42 USC 1395w-101 et seq. may choose to reimburse
21 more than the upper payment limit. A provider who dispenses and administers a
22 prescription drug product in this state to an individual in this state may not bill a
23 payor more than the upper payment limit to the patient regardless of whether a

1 plan subject to the Employee Retirement Income Security Act of 1974 or Part D of
2 Medicare under 42 USC 1395w-101 et seq. chooses to reimburse the provider above
3 the upper payment limit.

4 (5) PUBLIC INSPECTION. Information submitted to the board under this
5 section shall be open to public inspection only as provided under ss. 19.31 to 19.39.

6 (6) NO PROHIBITION ON MARKETING. Nothing in this section may be construed
7 to prevent a manufacturer from marketing a prescription drug product approved by
8 the federal food and drug administration while the prescription drug product is
9 under review by the board.

10 (7) APPEALS. A person aggrieved by a decision of the board may request an
11 appeal of the decision no later than 30 days after the board makes the
12 determination. The board shall hear the appeal and make a final decision no later
13 than 60 days after the appeal is requested. A person aggrieved by a final decision of
14 the board may petition for judicial review in a court of competent jurisdiction.

15 **SECTION 9.** 609.83 of the statutes is amended to read:

16 **609.83 Coverage of drugs and devices.** Limited service health
17 organizations, preferred provider plans, and defined network plans are subject to
18 ss. 632.853, 632.861, and 632.895 (6)(b), (16t), and (16v).

19 **SECTION 10.** 632.868 of the statutes is created to read:

20 **632.868 Insulin safety net programs.** (1) DEFINITIONS. In this section:

21 (a) "Manufacturer" means a person engaged in the manufacturing of insulin
22 that is self-administered on an outpatient basis.

23 (b) "Navigator" has the meaning given in s. 628.90 (3).

1 (c) "Patient assistance program" means a program established by a
2 manufacturer under sub. (3) (a).

3 (d) "Pharmacy" means an entity licensed under s. 450.06 or 450.065.

4 (e) "Urgent need of insulin" means having less than a 7-day supply of insulin
5 readily available for use and needing insulin in order to avoid the likelihood of
6 suffering a significant health consequence.

7 (f) "Urgent need safety net program" means a program established by a
8 manufacturer under sub. (2) (a).

9 **(2) URGENT NEED SAFETY NET PROGRAM.** (a) *Establishment of program.* No
10 later than July 1, 2026, each manufacturer shall establish an urgent need safety net
11 program to make insulin available in accordance with this subsection to individuals
12 who meet the eligibility requirements under par. (b).

13 (b) *Eligible individual.* An individual shall be eligible to receive insulin under
14 an urgent need safety net program if all of the following conditions are met:

- 15 1. The individual is in urgent need of insulin.
- 16 2. The individual is a resident of this state.
- 17 3. The individual is not receiving public assistance under ch. 49.
- 18 4. The individual is not enrolled in prescription drug coverage through an
19 individual or group health plan that limits the total cost sharing amount, including
20 copayments, deductibles, and coinsurance, that an enrollee is required to pay for a
21 30-day supply of insulin to no more than \$75, regardless of the type or amount of
22 insulin prescribed.

1 5. The individual has not received insulin under an urgent need safety net
2 program within the previous 12 months, except as allowed under par. (d).

3 (c) *Provision of insulin under an urgent need safety net program.* 1. In order
4 to receive insulin under an urgent need safety net program, an individual who
5 meets the eligibility requirements under par. (b) shall provide a pharmacy with all
6 of the following:

7 a. A completed application, on a form prescribed by the commissioner that
8 shall include an attestation by the individual, or the individual's parent or legal
9 guardian if the individual is under the age of 18, that the individual meets all of the
10 eligibility requirements under par. (b).

11 b. A valid insulin prescription.

12 c. A valid Wisconsin driver's license or state identification card. If the
13 individual is under the age of 18, the individual's parent or legal guardian shall
14 meet this requirement.

15 2. Upon receipt of the information described in subd. 1. a. to c., the pharmacist
16 shall dispense a 30-day supply of the prescribed insulin to the individual. The
17 pharmacy shall also provide the individual with the information sheet described in
18 sub. (8) (b) 2. and the list of navigators described in sub. (8) (c). The pharmacy may
19 collect a copayment, not to exceed \$35, from the individual to cover the pharmacy's
20 costs of processing and dispensing the insulin. The pharmacy shall notify the
21 health care practitioner who issued the prescription no later than 72 hours after the
22 insulin is dispensed.

23 3. A pharmacy that dispenses insulin under subd. 2. may submit to the

1 manufacturer, or the manufacturer's vendor, a claim for payment that is in
2 accordance with the national council for prescription drug programs' standards for
3 electronic claims processing, except that no claim may be submitted if the
4 manufacturer agrees to send the pharmacy a replacement of the same insulin in
5 the amount dispensed. If the pharmacy submits an electronic claim, the
6 manufacturer or vendor shall reimburse the pharmacy in an amount that covers
7 the pharmacy's acquisition cost.

8 4. A pharmacy that dispenses insulin under subd. 2. shall retain a copy of the
9 application form described in subd. 1. a.

10 (d) *Eligibility of certain individuals.* An individual who has applied for public
11 assistance under ch. 49 but for whom a determination of eligibility has not been
12 made or whose coverage has not become effective or an individual who has an
13 appeal pending under sub. (3) (c) 4. may access insulin under this subsection if the
14 individual is in urgent need of insulin. To access a 30-day supply of insulin, the
15 individual shall attest to the pharmacy that the individual is described in this
16 paragraph and comply with par. (c) 1.

17 (3) PATIENT ASSISTANCE PROGRAM. (a) *Establishment of program.* No later
18 than July 1, 2026, each manufacturer shall establish a patient assistance program
19 to make insulin available in accordance with this subsection to individuals who
20 meet the eligibility requirements under par. (b). Under the patient assistance
21 program, the manufacturer shall do all of the following:

22 1. Provide the commissioner with information regarding the patient

1 assistance program, including contact information for individuals to call for
2 assistance in accessing the patient assistance program.

3 2. Provide a hotline for individuals to call or access between 8 a.m. and 10 p.m.
4 on weekdays and between 10 a.m. and 6 p.m. on Saturdays.

5 3. List the eligibility requirements under par. (b) on the manufacturer's
6 website.

7 4. Maintain the privacy of all information received from an individual
8 applying for or participating in the patient assistance program and not sell, share,
9 or disseminate the information unless required under this section or authorized, in
10 writing, by the individual.

11 (b) *Eligible individual*. An individual shall be eligible to receive insulin under
12 a patient assistance program if all of the following conditions are met:

13 1. The individual is a resident of this state.

14 2. The individual, or the individual's parent or legal guardian if the individual
15 is under the age of 18, has a valid Wisconsin driver's license or state identification
16 card.

17 3. The individual has a valid insulin prescription.

18 4. The family income of the individual does not exceed 400 percent of the
19 poverty line as defined and revised annually under 42 USC 9902 (2) for a family the
20 size of the individual's family.

21 5. The individual is not receiving public assistance under ch. 49.

22 6. The individual is not eligible to receive health care through a federally
23 funded program or receive prescription drug benefits through the U.S. department

1 of veterans affairs, except that this subdivision does not apply to an individual who
2 is enrolled in a policy under Part D of Medicare under 42 USC 1395w-101 et seq. if
3 the individual has spent at least \$1,000 on prescription drugs in the current
4 calendar year.

5 7. The individual is not enrolled in prescription drug coverage through an
6 individual or group health plan that limits the total cost sharing amount, including
7 copayments, deductibles, and coinsurance, that an enrollee is required to pay for a
8 30-day supply of insulin to no more than \$75, regardless of the type or amount of
9 insulin needed.

10 (c) *Application for patient assistance program.* 1. An individual may apply to
11 participate in a patient assistance program by filing an application with the
12 manufacturer that established the patient assistance program, the individual's
13 health care practitioner if the practitioner participates in the patient assistance
14 program, or a navigator included on the list under sub. (8) (c). A health care
15 practitioner or navigator shall immediately submit the application to the
16 manufacturer. Upon receipt of an application, the manufacturer shall determine
17 the individual's eligibility under par. (b) and, except as provided in subd. 2., notify
18 the individual of the determination no later than 10 days after receipt of the
19 application.

20 2. If necessary to determine the individual's eligibility under par. (b), the
21 manufacturer may request additional information from an individual who has filed
22 an application under subd. 1. no later than 5 days after receipt of the application.
23 Upon receipt of the additional information, the manufacturer shall determine the

1 individual's eligibility under par. (b) and notify the individual of the determination
2 no later than 3 days after receipt of the requested information.

3 3. Except as provided in subd. 5., if the manufacturer determines under subd.
4 1. or 2. that the individual is eligible for the patient assistance program, the
5 manufacturer shall provide the individual with a statement of eligibility. The
6 statement of eligibility shall be valid for 12 months and may be renewed upon a
7 determination by the manufacturer that the individual continues to meet the
8 eligibility requirements under par. (b).

9 4. If the manufacturer determines under subd. 1. or 2. that the individual is
10 not eligible for the patient assistance program, the manufacturer shall provide the
11 reason for the determination in the notification under subd. 1. or 2. The individual
12 may appeal the determination by filing an appeal with the commissioner that shall
13 include all of the information provided to the manufacturer under subds. 1. and 2.
14 The commissioner shall establish procedures for deciding appeals under this
15 subdivision. The commissioner shall issue a decision no later than 10 days after the
16 appeal is filed, and the commissioner's decision shall be final. If the commissioner
17 determines that the individual meets the eligibility requirements under par. (b), the
18 manufacturer shall provide the individual with the statement of eligibility
19 described in subd. 3.

20 5. In the case of an individual who has prescription drug coverage through an
21 individual or group health plan, if the manufacturer determines under subd. 1. or 2.
22 that the individual is eligible for the patient assistance program but also
23 determines that the individual's insulin needs are better addressed through the use

1 of the manufacturer's copayment assistance program rather than the patient
2 assistance program, the manufacturer shall inform the individual of the
3 determination and provide the individual with the necessary coupons to submit to
4 a pharmacy. The individual may not be required to pay more than the copayment
5 amount specified in par. (d) 2.

6 (d) *Provision of insulin under a patient assistance program.* 1. Upon receipt
7 from an individual of the eligibility statement described in par. (c) 3. and a valid
8 insulin prescription, a pharmacy shall submit an order containing the name of the
9 insulin and daily dosage amount to the manufacturer. The pharmacy shall include
10 with the order the pharmacy's name, shipping address, office telephone number,
11 fax number, email address, and contact name, as well as any days or times when
12 deliveries are not accepted by the pharmacy.

13 2. Upon receipt of an order meeting the requirements under subd. 1., the
14 manufacturer shall send the pharmacy a 90-day supply of insulin, or lesser amount
15 if requested in the order, at no charge to the individual or pharmacy. The pharmacy
16 shall dispense the insulin to the individual associated with the order. The insulin
17 shall be dispensed at no charge to the individual, except that the pharmacy may
18 collect a copayment from the individual to cover the pharmacy's costs for processing
19 and dispensing in an amount not to exceed \$50 for each 90-day supply of insulin.
20 The pharmacy may not seek reimbursement from the manufacturer or a 3rd-party
21 payer.

22 3. The pharmacy may submit a reorder to the manufacturer if the individual's

1 eligibility statement described in par. (c) 3. has not expired. The reorder shall be
2 treated as an order for purposes of subd. 2.

3 4. Notwithstanding subds. 2. and 3., a manufacturer may send the insulin
4 directly to the individual if the manufacturer provides a mail-order service option,
5 in which case the pharmacy may not collect a copayment from the individual.

6 (4) EXCEPTIONS. (a) This section does not apply to a manufacturer that shows
7 to the commissioner's satisfaction that the manufacturer's annual gross revenue
8 from insulin sales in this state does not exceed \$2,000,000.

9 (b) A manufacturer may not be required to make an insulin product available
10 under sub. (2) or (3) if the wholesale acquisition cost of the insulin product does not
11 exceed \$8, as adjusted annually based on the U.S. consumer price index for all
12 urban consumers, U.S. city average, per milliliter or the applicable national council
13 for prescription drug programs' plan billing unit.

14 (5) CONFIDENTIALITY. All medical information solicited or obtained by any
15 person under this section shall be subject to the applicable provisions of state law
16 relating to confidentiality of medical information, including s. 610.70.

17 (6) REIMBURSEMENT PROHIBITION. No person, including a manufacturer,
18 pharmacy, pharmacist, or 3rd-party administrator, as part of participating in an
19 urgent need safety net program or patient assistance program may request or seek,
20 or cause another person to request or seek, any reimbursement or other
21 compensation for which payment may be made in whole or in part under a federal
22 health care program, as defined in 42 USC 1320a-7b (f).

23 (7) REPORTS. (a) Annually, no later than March 1, each manufacturer shall

1 report to the commissioner all of the following information for the previous calendar
2 year:

3 1. The number of individuals who received insulin under the manufacturer's
4 urgent need safety net program.

5 2. The number of individuals who sought assistance under the
6 manufacturer's patient assistance program and the number of individuals who
7 were determined to be ineligible under sub. (3) (c) 4.

8 3. The wholesale acquisition cost of the insulin provided by the manufacturer
9 through the urgent need safety net program and patient assistance program.

10 (b) Annually, no later than April 1, the commissioner shall submit to the
11 governor and the chief clerk of each house of the legislature, for distribution to the
12 legislature under s. 13.172 (2), a report on the urgent need safety net programs and
13 patient assistance programs that includes all of the following:

14 1. The information provided to the commissioner under par. (a).

15 2. The penalties assessed under sub. (9) during the previous calendar year,
16 including the name of the manufacturer and amount of the penalty.

17 (8) ADDITIONAL RESPONSIBILITIES OF COMMISSIONER. (a) *Application form.*
18 The commissioner shall make the application form described in sub. (2) (c) 1. a.
19 available on the office's website and shall make the form available to pharmacies
20 and health care providers who prescribe or dispense insulin, hospital emergency
21 departments, urgent care clinics, and community health clinics.

22 (b) *Public outreach.* 1. The commissioner shall conduct public outreach to

1 create awareness of the urgent need safety net programs and patient assistance
2 programs.

3 2. The commissioner shall develop and make available on the office's website
4 an information sheet that contains all of the following information:

5 a. A description of how to access insulin through an urgent need safety net
6 program.

7 b. A description of how to access insulin through a patient assistance
8 program.

9 c. Information on how to contact a navigator for assistance in accessing
10 insulin through an urgent need safety net program or patient assistance program.

11 d. Information on how to contact the commissioner if a manufacturer
12 determines that an individual is not eligible for a patient assistance program.

13 e. A notification that an individual may contact the commissioner for more
14 information or assistance in accessing affordable insulin options.

15 (c) *Navigators*. The commissioner shall develop a training program to provide
16 navigators with information and the resources necessary to assist individuals in
17 accessing appropriate long-term insulin options. The commissioner shall compile a
18 list of navigators that have completed the training program and are available to
19 assist individuals in accessing affordable insulin coverage options. The list shall be
20 made available on the office's website and to pharmacies and health care
21 practitioners who dispense and prescribe insulin.

22 (d) *Satisfaction surveys*. 1. The commissioner shall develop and conduct a
23 satisfaction survey of individuals who have accessed insulin through urgent need

1 safety net programs and patient assistance programs. The survey shall ask
2 whether the individual is still in need of a long-term solution for affordable insulin
3 and shall include questions about the individual's satisfaction with all of the
4 following, if applicable:

- 5 a. Accessibility to urgent-need insulin.
- 6 b. Adequacy of the information sheet and list of navigators received from the
7 pharmacy.
- 8 c. Helpfulness of a navigator.
- 9 d. Ease of access in applying for a patient assistance program and receiving
10 insulin from the pharmacy under the patient assistance program.

11 2. The commissioner shall develop and conduct a satisfaction survey of
12 pharmacies that have dispensed insulin through urgent need safety net programs
13 and patient assistance programs. The survey shall include questions about the
14 pharmacy's satisfaction with all of the following, if applicable:

- 15 a. Timeliness of reimbursement from manufacturers for insulin dispensed by
16 the pharmacy under urgent need safety net programs.
- 17 b. Ease in submitting insulin orders to manufacturers.
- 18 c. Timeliness of receiving insulin orders from manufacturers.

19 3. The commissioner may contract with a nonprofit entity to develop and
20 conduct the surveys under subds. 1. and 2. and to evaluate the survey results.

21 4. No later than July 1, 2028, the commissioner shall submit to the governor
22 and the chief clerk of each house of the legislature, for distribution to the legislature
23 under s. 13.172 (2), a report on the results of the surveys under subds. 1. and 2.

1 **(9) PENALTY.** A manufacturer that violates this section may be required to
2 forfeit not more than \$200,000 per month of violation, with the maximum forfeiture
3 increasing to \$400,000 per month if the manufacturer continues to be in violation
4 after 6 months and increasing to \$600,000 per month if the manufacturer continues
5 to be in violation after one year.

6 **SECTION 11.** 632.895 (6) (title) of the statutes is amended to read:

7 632.895 **(6)** (title) EQUIPMENT AND SUPPLIES FOR TREATMENT OF DIABETES;
8 INSULIN.

9 **SECTION 12.** 632.895 (6) of the statutes is renumbered 632.895 (6) (a) and
10 amended to read:

11 632.895 **(6)** (a) Every disability insurance policy ~~which~~ that provides coverage
12 of expenses incurred for treatment of diabetes shall provide coverage for expenses
13 incurred by the installation and use of an insulin infusion pump, coverage for all
14 other equipment and supplies, including insulin or any other prescription
15 medication, used in the treatment of diabetes, and coverage of diabetic self-
16 management education programs. ~~Coverage~~ Except as provided in par. (b),
17 coverage required under this subsection shall be subject to the same exclusions,
18 limitations, deductibles, and coinsurance provisions of the policy as other covered
19 expenses, except that insulin infusion pump coverage may be limited to the
20 purchase of one pump per year and the insurer may require the insured to use a
21 pump for 30 days before purchase.

22 **SECTION 13.** 632.895 (6) (b) of the statutes is created to read:

23 632.895 **(6)** (b) 1. In this paragraph:

1 a. “Cost sharing” means the total of any deductible, copayment, or
2 coinsurance amounts imposed on a person covered under a disability insurance
3 policy or self-insured health plan.

4 b. “Self-insured health plan” has the meaning given in s. 632.85 (1) (c).

5 2. Every disability insurance policy and self-insured health plan that covers
6 insulin and imposes cost sharing on prescription drugs may not impose cost sharing
7 on insulin in an amount that exceeds \$35 for a one-month supply of insulin.

8 3. Nothing in this paragraph prohibits a disability insurance policy or self-
9 insured health plan from imposing cost sharing on insulin in an amount less than
10 the amount specified under subd. 2. Nothing in this paragraph requires a disability
11 insurance policy or self-insured health plan to impose any cost sharing on insulin.

12 **SECTION 9123. Nonstatutory provisions; Insurance.**

13 (1) STAGGERED TERMS FOR PRESCRIPTION DRUG AFFORDABILITY REVIEW BOARD.
14 Notwithstanding the length of terms specified for the members of the prescription
15 drug affordability review board under s. 15.735 (1) (b) to (e), 2 of the initial
16 members shall be appointed for terms expiring on May 1, 2027; 2 of the initial
17 members shall be appointed for terms expiring on May 1, 2028; 2 of the initial
18 members shall be appointed for terms expiring on May 1, 2029; and 2 of the initial
19 members shall be appointed for terms expiring on May 1, 2030.

20 (2) PRESCRIPTION DRUG IMPORTATION PROGRAM. The commissioner of
21 insurance shall submit the first report required under s. 601.575 (5) by the next
22 January 1 or July 1, whichever is earliest, that is at least 180 days after the date the
23 prescription drug importation program is fully operational under s. 601.575 (4).

1 The commissioner of insurance shall include in the first 3 reports submitted under
2 s. 601.575 (5) information on the implementation of the audit functions under s.
3 601.575 (1) (n).

4 (3) PRESCRIPTION DRUG PURCHASING ENTITY. During the 2025-27 fiscal
5 biennium, the office of the commissioner of insurance shall conduct a study on the
6 viability of creating or implementing a state prescription drug purchasing entity.

7 **SECTION 9223. Fiscal changes; Insurance.**

8 (1) OFFICE OF PRESCRIPTION DRUG AFFORDABILITY. In the schedule under s.
9 20.005 (3) for the appropriation to the office of the commissioner of insurance under
10 s. 20.145 (1) (g), the dollar amount for fiscal year 2025-26 is increased by \$1,957,300
11 to provide \$500,000 in onetime implementation costs for establishing an office of
12 prescription drug affordability in the office of the commissioner of insurance and
13 \$1,457,300 to authorize 16.0 PR positions within the office of prescription drug
14 affordability, including 5.0 insurance examiners, 4.0 policy initiatives advisors, 2.0
15 attorneys, 1.0 insurance program manager, 2.0 insurance administrators, and 2.0
16 operations program associates. In the schedule under s. 20.005 (3) for the
17 appropriation to the office of the commissioner of insurance under s. 20.145 (1) (g),
18 the dollar amount for fiscal year 2026-27 is increased by \$1,871,100 to fund the
19 positions authorized under this subsection.

20 **SECTION 9423. Effective dates; Insurance.**

21 (1) PRESCRIPTION DRUG AFFORDABILITY REVIEW BOARD. The treatment of ss.
22 15.07 (3) (bm) 7., 15.735, 601.78, 601.785, and 601.79 and subch. VI (title) of ch. 601
23 and SECTION 9123 (1) of this act take effect on the first day of the 7th month
24 beginning after publication.

(2) COST-SHARING CAP ON INSULIN. The treatment of ss. 609.83 and 632.895 (6) (title), the renumbering and amendment of s. 632.895 (6), and the creation of s. 632.895 (6) (b) take effect on the first day of the 4th month beginning after publication.”.

5 (END)